MBX Biosciences, Inc. Common Stock (MBX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $2.64B
Last updated: Nov 17, 2026 at 4:15 PM ET
MBX Biosciences, Inc. Common Stock (MBX) Statistics
MBX Biosciences, Inc. Common Stock (MBX) has a market cap of $2.64B and an enterprise value of $2.48B. Its share count is up 41.99% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 6.13% below the market cap, as cash exceeds debt.
| Market Cap | $2.64B |
|---|---|
| Enterprise Value | $2.48B |
| Latest price (Nov 17, 2026) | $53.10 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 114.20% over 52 weeks and trades 4.17% below its 50-day average.
| Beta (1Y) | 1.31 |
|---|---|
| 52-Week Change | +114.20% |
| 1-Month Change | +1.18% |
| 3-Month Change | -22.37% |
| 6-Month Change | +74.73% |
| Total Return (1Y) | +114.20% |
| Return vs SPY (1Y) | +89.88% |
| Max Drawdown (1Y) | -37.60% |
| Max Drawdown (3Y) | -77.71% |
| Sharpe Ratio (1Y) | 0.93 |
| Correlation with SPY (1Y) | 0.24 |
| 50-Day Average | $55.41 |
| 200-Day Average | $46.48 |
| 52-Week Range | $26.00 to $72.64 |
| RSI (14 Days) | 47.9 |
| Average Volume (20 Days) | 508.44K |
Financial Position
Current assets cover 19.58x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 19.58x |
|---|---|
| Quick Ratio | 19.58x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -30.68% and return on assets is -28.98% over the last 12 months.
| Return on Equity (ROE) | -30.68% |
|---|---|
| Return on Assets (ROA) | -28.98% |
Scores
MBX has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$60.00K |
| Operating Income | -$160.33M |
| Pretax Income | -$145.09M |
| Net Income | -$145.09M |
| Reported EPS (TTM) | -$3.07 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 94.47% of the $500.62M in total assets.
| Cash and Equivalents | $161.69M |
|---|---|
| Total Debt | $0 |
| Net Cash | $161.69M |
| Net Cash Per Share | $3.33 |
| Working Capital | $467.60M |
| Shareholder Equity | $472.95M |
| Book Value Per Share | $9.74 |
| Total Assets | $500.62M |
| Total Liabilities | $27.67M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $3.32M of capital spending, operating cash flow left -$99.33M of free cash flow.
| Operating Cash Flow | -$96.01M |
|---|---|
| Capital Expenditures | $3.32M |
| Free Cash Flow | -$99.33M |
| FCF Per Share | -$2.06 |
| Depreciation and Amortization | $2.10M |
| Share Repurchases | $1.05M |
Trailing 12 months through Sep 30, 2026.
Dividends and Yields
MBX does not pay a dividend. Its free cash flow yield is -3.85%.
| FCF Yield | -3.85% |
|---|---|
| Buyback Yield | -7.05% |
| Shareholder Yield | -7.05% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About MBX
What is MBX's market cap?
MBX Biosciences, Inc. Common Stock has a market cap of $2.64B. Its enterprise value, which adds debt and subtracts cash, is $2.48B.
How many shares of MBX are outstanding?
MBX Biosciences, Inc. Common Stock has 48.56M shares outstanding. The count is up 41.99% from a year earlier.
Does MBX pay a dividend?
No. MBX Biosciences, Inc. Common Stock does not pay a dividend.
How much debt does MBX have?
MBX Biosciences, Inc. Common Stock has $0 of total debt and $161.69M of cash and equivalents, a net cash position of $161.69M.
MBX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors